Compare Adaptive Biotechnologies Corp (ADPT) vs Indonesia Energy Corporation Limited (INDO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Indonesia Energy Corporation Limited — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Indonesia Energy Corporation Limited trades at $2.84 (market cap $44.31M). The key difference: Adaptive Biotechnologies Corp is far larger — about 75.2× Indonesia Energy Corporation Limited's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals.
| ADPT | INDO | |
|---|---|---|
Market Cap | $3.33B | $44.31M |
Sector | Health | Energy |
52-Week High | $22.37 | $6.74 |
52-Week Low | $10.24 | $2.49 |
Enterprise Value | $3.19B | $39.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
INDO trades at $2.79 with no recent price movement. The stock shows mixed technical signals with a bullish overall rating but bearish moving averages. Fundamentally, the company reported negative profitability metrics with a -253.4% net income margin on $2M revenue in 2025, though recent news highlights operational progress with new well drilling at the Kruh Block. Analyst consensus is unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of drilling operations to improve financial performance. Key opportunities include potential revenue growth from new wells, while risks center on continued negative cash flow and profitability challenges. The stock presents speculative potential for investors betting on operational turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →
